Overview

A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

Status:
Completed

Trial end date:
2019-08-19

Target enrollment:

Participant gender:

Summary

The objective of the CAPACITY-HFpEF study is to evaluate the safety and efficacy of IW-1973 compared with placebo when administered daily for approximately 12 weeks to patients with HFpEF. The study will evaluate the effect of oral IW-1973 on peak exercise capacity in patients with HFpEF, with or without permanent or persistent atrial fibrillation.

Phase:

Phase 2

Details

Lead Sponsor:

Cyclerion Therapeutics
Ironwood Pharmaceuticals, Inc.

Treatments:

Praliciguat